

Supplementary Table

Table 1: Reported cases of biologics used in the management of CARD 14 associated papulosquamous eruption (CAPE)

Report	Number	Biologic	Dosage	Response
Craiglow <i>et al.</i> ^{S1}	6	Ustekinumab	0.7 mg – 1.2 mg/Kg q 12 weeks	Near complete response -5/6 Partial response -1/6
Kiszewski <i>et al.</i> ^{S3}	1	Ustekinumab	10.8 mg q 12 weeks	Near complete
Signa <i>et al.</i> ^{S4}	2	Ustekinumab	2 mg/Kg q 12 weeks	Complete remission
Nieto- Benito <i>et al.</i> ^{S5}	1	Ustekinumab	90 mg q 12 weeks	Near complete
Frare <i>et al.</i> ^{S6}	2	Ustekinumab	45 mg q 12 weeks	Partial
Noguiera <i>et al.</i> ^{S7}	1	Ustekinumab	0.75-1 mg/Kg q 8 weeks	Near complete
Niedzwiedz <i>et al.</i> ^{S8}	1	Adalimumab Ustekinumab	40 mg q 1-2 week 1-1.8 mg/Kg q 8-12 week	Partial response Near complete
Chiramel <i>et al.</i> ^{S2}	1	Secukinumab	75 mg/ week for 5 week 150 mg/week monthly	Near complete
Dai S <i>et al.</i> ^{S9}	1	Secukinumab	150 mg/week – 5 weeks; 150 mg monthly	Near complete
Present report	1	Secukinumab	150 mg every 15 days for 4 doses and then monthly	Complete remission

Supplementary References:

S1. Craiglow BG, Boyden LM, Hu R, Virtanen M, Su J, Rodriguez G, *et al.* CARD14-associated papulosquamous eruption: A spectrum including features of psoriasis and pityriasis rubra pilaris. *J Am Acad Dermatol* 2018;79:487-94.

S2. Chiramel MJ, Sathishkumar D, Jayakrishna A. Safety and efficacy of secukinumab in a child with CARD14-associated papulosquamous eruption: A case report and review of literature. *Indian Dermatol. Online J* 2024;15:634-6.

S3. Kiszewski AE, De Almeida Jr HL. Successful treatment with ustekinumab in CARD14-associated papulosquamous eruption in a Brazilian child. *Dermatol Ther* 2022;35:e15939

S4. Signa S, Campione E, Rusmini M, Chiesa S, Grossi A, Omenetti A, *et al.* Whole exome sequencing approach to childhood onset familial erythrodermic psoriasis unravels a novel mutation of CARD14 requiring unusual high doses of ustekinumab. *Pediatr Rheumatol* 2019;17;38.

S5. Nieto-Benito L.M, Baniandr s-Rodr guez O, Moreno-Torres A, Hern ndez-Mart n A, Torrelo-Fern ndez A, Campos-Dom nguez M. Clinical response to ustekinumab in *CARD14*-associated papulosquamous eruption (CAPE) with a new missense mutation in *CARD14*: A case report and systematic review. *Acad Dermatol Venereol* 2020;34.

S6. Frare CP, Blumstein AJ, Paller AS, Pieretti L, Choate KA, Bowcock AM, *et al.* *CARD14*-associated papulosquamous eruption (CAPE) in pediatric patients: Three additional cases and review of the literature. *Pediatr Dermatol* 2021;38:1237-42.

S7. Nogueira M, Reis J, Abreu M, Coelho A , Reis C udiaF, Machado S. A child with *CARD14*-associated papulosquamous eruption (CAPE) successfully treated with ustekinumab. *Pediatr Dermatol* 2023;40:1104-6.

S8. Nied zwied  M, Narbutt J, Siekierko A, Skibi ska M gorzata, Kwiek B, Sobolewska-Sztychny D, *et al.* Case report: Successful treatment with biologics in a pediatric patient with a severe inflammatory skin disease and novel *CARD14* mutation. *Front Med* 2024;11.

S9. Dai S, Zhang S, Wang C, Lin X, Lin Z. *CARD14* Missense Variant Underlying *CARD14*-Associated Papulosquamous Eruption with Beneficial Response to Secukinumab. *JID Innov.* 2022 Dec 11;3:100174.